Responsivity of the Striatal Dopamine System to Methylphenidate—A Within-Subject I-123-β-CIT-SPECT Study in Male Children and Adolescents With Attention-Deficit/Hyperactivity Disorder

URN to cite this document:

urn:nbn:de:bvb:355-epub-576291 Copy

DOI to cite this document:

10.5283/epub.57629 Copy

Aster, Hans-Christoph ; Romanos, Marcel ; Walitza, Susanne ; Gerlach, Manfred ; Mühlberger, Andreas ; Rizzo, Albert ; Andreatta, Marta ; Hasenauer, Natalie ; Hartrampf, Philipp E. ; Nerlich, Kai ; Reiners, Christoph ; Lorenz, Reinhard ; Buck, Andreas K. ; Deserno, Lorenz

License: Creative Commons Attribution 4.0 PDF - Published Version (912kB)

Date of publication of this fulltext: 29 Feb 2024 13:01

---

Alternative links to fulltext:DOIPublisher

---

Details

Item type:	Article
Höhe Gebühr (aus OpenAPC):	2876.8
Institution der Zahlung:	Wuerzburg U
Journal or Publication Title:	Frontiers in Psychiatry
Publisher:	Frontiers
Place of Publication:	LAUSANNE
Volume:	13
Date:	2022
Institutions:	Medicine > Lehrstuhl für Psychiatrie und Psychotherapie
Identification Number:	Value Type 10.3389/fpsyt.2022.804730 DOI
Keywords:	DEFICIT-HYPERACTIVITY-DISORDER; VENTRAL STRIATUM; TRANSPORTER; ADHD; BINDING; PATHOPHYSIOLOGY; DYSREGULATION; AVAILABILITY; METAANALYSIS; MEDICATION; methylphenidate; attention deficit; hyperactivity disorder (ADHD); striatum; single photon emission computed tomography (SPECT); responsivity; caudate nucleus; dopamine transporter (DAT)
Dewey Decimal Classification:	600 Technology > 610 Medical sciences Medicine
Status:	Published
Refereed:	Yes, this version has been refereed
Created at the University of Regensburg:	Yes
Item ID:	57629

Preview

Indexed in

Web of Science

Export bibliographical data

ASCII CitationAtomBibTeXData Cite XMLDataCite XML OAIDublin CoreDublin Core (LZV)EndNoteHTML CitationJSONJSON LDMETSMODSOPENAIREOpenAPCRDF+N-TriplesRDF+N3RDF+XMLReferReference ManagerSimple MetadataXMLopenCostxMetaDissPlus

---

Abstract

Background:Methylphenidate (MPH) is the first-line pharmacological treatment of attention-deficit/hyperactivity disorder (ADHD). MPH binds to the dopamine (DA) transporter (DAT), which has high density in the striatum. Assessments of the striatal dopamine transporter by single positron emission computed tomography (SPECT) in childhood and adolescent patients are rare but can provide insight on ...

Abstract

Background:Methylphenidate (MPH) is the first-line pharmacological treatment of attention-deficit/hyperactivity disorder (ADHD). MPH binds to the dopamine (DA) transporter (DAT), which has high density in the striatum. Assessments of the striatal dopamine transporter by single positron emission computed tomography (SPECT) in childhood and adolescent patients are rare but can provide insight on how the effects of MPH affect DAT availability. The aim of our within-subject study was to investigate the effect of MPH on DAT availability and how responsivity to MPH in DAT availability is linked to clinical symptoms and cognitive functioning. MethodsThirteen adolescent male patients (9-16 years) with a diagnosis of ADHD according to the DSM-IV and long-term stimulant medication (for at least 6 months) with MPH were assessed twice within 7 days using SPECT after application of I-123-beta-CIT to examine DAT binding potential (DAT BP). SPECT measures took place in an on- and off-MPH status balanced for order across participants. A virtual reality continuous performance test was performed at each time point. Further clinical symptoms were assessed for baseline off-MPH. ResultsOn-MPH status was associated with a highly significant change (-29.9%) of striatal DAT BP as compared to off-MPH (t = -4.12, p = 0.002). A more pronounced change in striatal DAT BP was associated with higher off-MPH attentional and externalizing symptom ratings (Pearson r = 0.68, p = 0.01). Striatal DAT BP off-MPH, but not on-MPH, was associated with higher symptom ratings (Pearson r = 0.56, p = 0.04). ConclusionOur findings corroborate previous reports from mainly adult samples that MPH changes striatal DAT BP availability and suggest higher off-MPH DAT BP, likely reflecting low baseline DA levels, as a marker of symptom severity.

---

---

Metadata last modified: 05 Sep 2024 08:34

Owner only: item control page

Download Statistics

Download Statistics

Download Statistics

Download Statistics

Downloads

Downloads per month over past year

Altmetric

Altmetric

Altmetric

Alternative Statistics (altmetrics)

More literature (via CORE)

More literature (via CORE)

More literature (via CORE)

More literature (via CORE)